公开(公告)号：EP2861246A2

公开(公告)日：2015-04-22

申请号：EP13807326.7

申请日：2013-06-18

申请人： Omeros Corporation ,  University of Leicester

发明人： SCHWAEBLE, Hans-wilhelm ,  DEMOPULOS, Gregory, A. ,  DUDLER, Thomas ,  GRAY, Patrick

IPC分类号： A61K39/00

CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

摘要： In one aspect, the invention provides methods and compositions for inhibiting MASP-3 -dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3 -dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

公开(公告)号：EP3057993A1

公开(公告)日：2016-08-24

申请号：EP14853910.9

申请日：2014-10-17

申请人： Omeros Corporation ,  University of Leicester

发明人： DEMOPULOS, Gregory, A. ,  DUDLER, Thomas ,  SCHWAEBLE, Hans-wilhelm

IPC分类号： C07K16/40

摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.

摘要翻译： 一方面，本发明提供了抑制患有或有发生血栓性微血管病（TMA）风险的活体中MASP-2依赖性补体活化作用的方法。 该方法包括向有需要的受试者施用有效抑制MASP-2依赖性补体激活的量的MASP-2抑制剂的步骤。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化相关的细胞损伤，同时保持免疫系统的经典（Clq依赖性）途径组分完整。

公开(公告)号：EP4288098A1

公开(公告)日：2023-12-13

申请号：EP22750462.8

申请日：2022-02-04

申请人： Omeros Corporation

发明人： DEMOPULOS, Gregory, A. ,  DUDLER, Thomas ,  LYNCH, Nicholas, James ,  SCHWAEBLE, Hans-wilhelm ,  SHAFFER, Kathleen ,  YABUKI, Munehisa

IPC分类号： A61K39/395 ,  A61P31/14 ,  A61P11/00 ,  C07K16/40 ,  G01N33/53 ,  G01N33/564